Chk2 Inhibitor II hydrate
SIGMA/C3742 - ≥98% (HPLC)
Synonym: 2-
CAS Number: 516480-79-8 (anhydrous)
Empirical Formula (Hill Notation): C20H14ClN3O2 · xH2O
Molecular Weight: 363.80 (anhydrous basis)
MDL Number: MFCD08276917
Linear Formula: C20H14ClN3O2 · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | off-white to tan |
| form | solid |
| InChI | 1S/C20H14ClN3O2/c21-14-4- |
| InChI key | UXGJAOIJSROTTN-UHFFFAOYSA |
| originator | Johnson & Johnson |
| Quality Level | 100 ![]() |
| SMILES string | O=C(C1=CC=C2C(N=C(C3=CC=C |
| solubility | DMSO: ≥2 mg/mL (warmed) |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer. |
| Biochem/physiol Actions: | Chk2 Inhibitor II is a checkpoint kinase 2 inhibitor, which controls the p53 response to DNA breaks induced by radiation, leading to apoptosis. Protection of T-cells from apoptosis implies use as an adjuvant for radiation therapy in cancer. IC50 = 15 nM; Ki = 37 nM. Chk2 Inhibitor II shows 1000-fold greater selectivity for the Chk2 serine/threonine kinase than for the Cdk1/B and CK1 kinases (for which IC50 = 12 μM and 17 μM, respectively). Chk2 Inhibitor II weakly inhibits a panel of 31 other kinases (<25% inhibition at a concentration of 10 μM and prevents apoptosis of human CD4+ and CD8+ T-cells subjected to ionizing radiation (EC50 = 3 μM and 7.6 μM, respectively). |
| Features and Benefits: | This compound was developed by Johnson & Johnson . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |

